Peggy Wallace
Known title: DirectorCIK: 0001876466
Peggy Wallace's purchase track record
Peggy Wallace has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/15/2022 | CGTX | $15K | +25.5% | +15.9% | +3.0% |
| 10/13/2021 | CGTX | $36K | -48.7% | -76.4% | +1.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CGTX | ▲ Buy | Grant | 25,000 | $0 | 6/17/2026 | View on chart |
| CGTX | ▲ Buy | Grant | 34,000 | $0 | 6/18/2025 | View on chart |
| CGTX | ▲ Buy | Grant | 8,500 | $0 | 6/7/2024 | View on chart |
| CGTX | ▲ Buy | Grant | 6,000 | $0 | 6/9/2023 | View on chart |
| CGTX | ▲ Buy | Open Market | 12,500 | $15K | 11/15/2022 | View on chart |
| CGTX | ▼ Sell | Other | 22,461 | $0 | 9/27/2022 | View on chart |
| CGTX | ▲ Buy | Open Market | 3,000 | $36K | 10/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20
Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.